Document Detail

Additive effects of Cox-1 and Cox-2 inhibition on breast cancer in vitro.
MedLine Citation:
PMID:  16964399     Owner:  NLM     Status:  MEDLINE    
We hypothesized that combined treatment with Cox-1 and Cox-2 specific inhibitiors would exhibit synergistic effects against breast cancer in vitro. Two human breast cancer cell lines (HTB26, MCF-7) were treated with catechin (Cox-1 inhibitor) or NS398 (Cox-2 inhibitor) at 100 microM as both single and combined treatments. Reductions in cell growth were observed in both cell lines at 24 and 72 h in both single and combined treatments (p<0.001). Combined treatment produced a significantly greater inhibition as compared to single agents alone. Upon cell cycle evaluation, Cox-1 and -2 antagonism increased G1 and G2 phase fractions in MCF-7 cells (p<0.001 and p<0.05 respectively). No additive changes were observed when the two agents were combined. An increase in the G2 phase was observed in the HTB26 cells when treated with NS398 alone (p<0.001). However, a decrease in the S-phase was observed when these cells were treated with NS398, as a single agent (p<0.01) or when the two agents were combined (p<0.01). The significant and additive effects exhibited by the combination of Cox-1 and -2 inhibitors and their effects on cell cycle suggest that these agents could become an effective treatment modality for carcinoma of the breast.
David W McFadden; Dale R Riggs; Barbara J Jackson; Cynthia Cunningham
Related Documents :
22906069 - High-energy compounds promote physiological processing of alzheimer's amyloid-β precur...
15197559 - Differences in centromere positioning of cycling and postmitotic human cell types.
22661379 - Catalase and estradiol inhibit mitochondrial protein s-glutathionylation.
1567429 - The phosphorylation of retinoblastoma gene product in human myeloid leukemia cells duri...
7692289 - Induction of chromatid breaks and tetraploidy in chinese hamster ovary cells by treatme...
8087109 - Trichomonas vaginalis: dominant g2 period and g2 phase arrest in a representative of an...
1087319 - Ontogeny of the antibody-forming cell line in mice. ii. maturation of b cells during fe...
9772099 - Differential induction of apoptosis in activated and resting t cells by 2,3,7,8-tetrach...
16987179 - The f-box protein grr1 regulates the stability of ccn1, cln3 and hof1 and cell morphoge...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  International journal of oncology     Volume:  29     ISSN:  1019-6439     ISO Abbreviation:  Int. J. Oncol.     Publication Date:  2006 Oct 
Date Detail:
Created Date:  2006-09-11     Completed Date:  2006-12-14     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9306042     Medline TA:  Int J Oncol     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  1019-23     Citation Subset:  IM    
Department of Surgery, Robert C. Byrd Health Sciences Center, West Virginia University, Morgantown, WV 26506, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Breast Neoplasms / enzymology*
Cell Cycle / drug effects
Cell Line, Tumor
Cell Proliferation / drug effects
Cyclooxygenase 1 / drug effects*
Cyclooxygenase 2
Cyclooxygenase 2 Inhibitors / pharmacology*
Cyclooxygenase Inhibitors / pharmacology*
Drug Synergism
Membrane Proteins / antagonists & inhibitors*
Reg. No./Substance:
0/Cyclooxygenase 2 Inhibitors; 0/Cyclooxygenase Inhibitors; 0/Membrane Proteins; EC 1; EC 2; EC protein, human

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  EG-1 interacts with c-Src and activates its signaling pathway.
Next Document:  Extracellular acidosis elevates carbonic anhydrase IX in human glioblastoma cells via transcriptiona...